<a href="https://laohu8.com/S/KPRX">Kiora Pharmaceuticals</a> Reports Consistent <a href="https://laohu8.com/S/QTWO">Q2</a> Net Loss of $2.2 Million; R&D Expenses Rise Due to Clinical Trials
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced its financial results for the second quarter of 2025. The company reported a net loss of $2.2 million for this period, consistent with the net loss reported in the second quarter of 2024. Kiora's R&D expenses for Q2 2025 were $2.6 million, before accounting for $1.7 million in reimbursable expenses from Théa, reflecting an increase compared to the $2.0 million in R&D expenses for Q2 2024, which had $1.1 million in offsetting reimbursable expenses. This increase is mainly attributed to clinical trial activities. General and administrative expenses decreased slightly to $1.4 million from $1.5 million in the same quarter of the previous year. The company ended the quarter with $20.7 million in cash, cash equivalents, and short-term investments. Additionally, Kiora maintained a projected cash runway into late 2027, extending beyond anticipated data readouts for its KLARITY and ABACUS-2 trials, with potential for further extension through partnership milestones. In terms of operational updates, Kiora initiated KLARITY, a Phase 2 clinical trial for KIO-104 aimed at treating retinal inflammation, and extended market exclusivity of KIO-104 into 2043 with a new patent for ocular inflammatory disease treatments.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiora Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 261730) on August 08, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.